ArticleAmerican journal of translational research2019
LncRNA LOXL1-AS1 promotes invasion and proliferation of non-small-cell lung cancer through targeting miR-324-3p.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Long non-coding RNA LOXL1 antisense RNA 1 promotes the malignancy of non-small cell lung cancer cells via modulating the microRNA-122-5p/E2F transcription factor 3 axis.Molecular genetics and genomics : MGG · 2026Article
- Icariin mediates autophagy and apoptosis of hepatocellular carcinoma cells induced by the β-catenin signaling pathway through lncRNA LOXL1-AS1.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Silencing of LINC01278 promotes sensitivity of non-small cell lung cancer cells to osimertinib by targeting miR-324-3p/ZFX axis.Cytotechnology · 2025Article
- Involvement of long non-coding RNA LOXL1-AS1 in the tumourigenesis and development of malignant tumours: a narrative review.Translational cancer research · 2024Review
- Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors.Clinical and experimental medicine · 2024Review
- Potential role of lncRNA LOXL1-AS1 in human cancer development: a narrative review.Translational cancer research · 2024Review
- LOXL1-AS1 inhibits JAK2 ubiquitination and promotes cholangiocarcinoma progression through JAK2/STAT3 signaling.Cancer gene therapy · 2024Article
- A comprehensive review on lncRNA LOXL1-AS1: molecular mechanistic pathways of lncRNA LOXL1-AS1 in tumorigenicity of cancer cells.Frontiers in oncology · 2024Review
- Soft Tissue Ewing Sarcoma Cell Drug Resistance Revisited: A Systems Biology Approach.International journal of environmental research and public health · 2023Article
- LncRNA LOXL1-AS1 Facilitates the Oncogenic Character in Cervical Cancer by the miR-526b-5p /LYPLA1 Axis.Biochemical genetics · 2022Article
- CTBP1-AS2 promoted non-small cell lung cancer progression via sponging the miR-623/MMP3 axis.Environmental science and pollution research international · 2022Article
- Down-regulation of ZNF252P-AS1 alleviates ovarian cancer progression by binding miR-324-3p to downregulate LY6K.Journal of ovarian research · 2022Article
- MiR-211-5p Inhibits the Biological Behaviors of Colorectal Cancer via SPARC-Related Growth Factor Pathways.Journal of Cancer · 2022Article
- A review on the role of miRNA-324 in various diseases.Frontiers in genetics · 2022Review
- LOXL1-AS1 communicating with TIAR modulates vasculogenic mimicry in glioma via regulation of the miR-374b-5p/MMP14 axis.Journal of cellular and molecular medicine · 2022Article
- Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.International journal of molecular sciences · 2021Review
- Inhibition of LOXL1-AS1 alleviates oxidative low-density lipoprotein induced angiogenesis via downregulation of miR-590-5p mediated KLF6/VEGF signaling pathway.Cell cycle (Georgetown, Tex.) · 2021Article
- lncRNA LOXL1-AS1 promotes liver cancer cell proliferation and migration by regulating the miR-377-3p/NFIB axis.Oncology letters · 2021Article
- LOXL1-AS1 contributes to the proliferation and migration of laryngocarcinoma cells through miR-589-5p/TRAF6 axis.Cancer cell international · 2020Article
- Long Non-Coding RNA LOXL1-AS1 Enhances Colorectal Cancer Proliferation, Migration and Invasion Through miR-708-5p/CD44-EGFR Axis.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
LncRNAs are played crucial roles in athogenesis of NSCLC. LOXL1-AS1 involved in development of several tumors. So far, there is no study about expression and function pattern of the LOXL1-AS1 in NSCLC. In this reference, we firstly proved that LOXL1-AS1 was overexpressed in NSCLC cell lines (H23, A549, H1299 and SPC-A1) compared to 16HBE cell. The expression of LOXL1-AS1 was overexpressed in NSCLC specimens than adjacent control specimens. We found that 29 of 40 cases showed higher LOXL1-AS1 expression in NSCLC samples as compared to adjacent control specimens. Ectopic expression of LOXL1-AS1 promoted H1299 cell and H23 cell proliferation. LOXL1-AS1 overexpression promoted ki-67 and cyclin D1 expression in the NSCLC cell. Overexpression of LOXL1-AS1 promoted cell invasion and induced N-cadherin and Vimentin expression and suppressed E-cadherin expression in the NSCLC cell. LOXL1-AS1 acts as one sponge for miR-324-3p in NSCLC cell. Moreover, the expression of miR-324-3p was lower in NSCLC specimens than adjacent control specimens. We found that 24 of 40 cases showed lower miR-324-3p expression in NSCLC samples as compared to adjacent control specimens. Further correlation assay indicated a negative association between miR-324-3p and LOXL1-AS1 expression. miR-324-3p restoration attenuates the function of LOXL1-AS1 overexpression on NSCLC cell. These results indicated that LOXL1-AS1 enhanced NSCLC cell proliferation and invasion via sponging miR-324-3p in NSCLC cell.
Indexed as
Identifiers
31737192PMC6834493W2993535690What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.